Top Arecoline Secrets
MI-CP151 was a stage 1b randomised, double-blind, placebo managed, dose-escalation, multicentre research To judge several intravenous doses of sifalimumab, in adult individuals with dermatomyositis or polymyositis (NCT00533091). Primary trial aims had been To judge the safety and tolerability of sifalimumab in dermatomyositis or polymyositis client